BNZ-1 Drug Asset Due Diligence Report 2026

This BNZ-1 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether BNZ-1 can convert its Synthetic peptide profile and IL-15 x IL-2 x IL-9 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	BNZ-1 (query alias: BNZ-1)
Modality / target	Synthetic peptide; IL-15 x IL-2 x IL-9; IL-15 inhibitors, IL-2 inhibitors, IL-9 inhibitors
Highest global status	Phase 2
Originator	Bioniz Therapeutics, Inc.
Active developers	National Institutes of Health, Bioniz Therapeutics, Inc.

The MCP disease footprint includes Cutaneous T-Cell Lymphoma, Lymphoid Leukemia, Alopecia Areata. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05589610	Phase 2	Completed	36	Primary endpoint not disclosed in English source
NCT03739541	Phase 1	Completed	6	Primary endpoint not disclosed in English source
NCT03532958	Phase 2	Withdrawn	0	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata

Phase 2; n=36; evaluation: Not stated in English source. Reported fields: Number of Treatment Emergent Adverse Events = 27 Pts

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Phase 2; n=25; evaluation: Positive. Reported fields: SALT(less than or equal to 20; week 24; baseline SALT of 35 to 100) = 20 %

Effective Treatment with the Selective Cytokine Inhibitor BNZ-1 Reveals the Cytokine Dependency of T-LGL Leukemia.

Phase 1/2; n=50; evaluation: Not stated in English source. Reported fields: Clinical partial responses = 20 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

BNZ-1 addresses Cutaneous T-Cell Lymphoma, Lymphoid Leukemia, Alopecia Areata. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
Not disclosed	Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates	Phase 2	US$307.5M milestones
2020-01-09	Almirall enters into an option agreement to acquire Bioniz Therapeutics and to establish a broad research agreement to further expand its innovative pipeline in medical dermatology	Phase 1/2	US$15.0M upfront

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Improved oral pharmaceutical formulations of therapeutic peptides and proteins”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO